Category: biologic
Aliases: Opdivo, anti-PD-1 mAb
Fully human IgG4 (S228P hinge-stabilised) mAb binding PD-1 on T cells → blocks PD-L1/L2 inhibitory signals → restores anti-tumour T cell activity. Combined with ipilimumab (anti-CTLA-4) in melanoma, RCC, MSI-high CRC, and mesothelioma for synergistic response. Approved across melanoma, NSCLC, RCC, HCC, CRC, gastric, urothelial, head & neck, Hodgkin, and more.
IV: 600h